The best treatment response was shown in patients with high tumor expression levels of programmed death receptor ligand-1 (PD-L1), usually with a tumor proportional score (TPS, % of tumor cells expressing PD-L1) above 50%. The gene discussed is CD274; the disease is neoplasm.